SG11201500125QA - Inhibitors of the fibroblast growth factor receptor - Google Patents
Inhibitors of the fibroblast growth factor receptorInfo
- Publication number
- SG11201500125QA SG11201500125QA SG11201500125QA SG11201500125QA SG11201500125QA SG 11201500125Q A SG11201500125Q A SG 11201500125QA SG 11201500125Q A SG11201500125Q A SG 11201500125QA SG 11201500125Q A SG11201500125Q A SG 11201500125QA SG 11201500125Q A SG11201500125Q A SG 11201500125QA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- growth factor
- factor receptor
- fibroblast growth
- fibroblast
- Prior art date
Links
- 108091008794 FGF receptors Proteins 0.000 title 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261670379P | 2012-07-11 | 2012-07-11 | |
US201261746666P | 2012-12-28 | 2012-12-28 | |
PCT/US2013/050106 WO2014011900A2 (fr) | 2012-07-11 | 2013-07-11 | Inhibiteurs du récepteur du facteur de croissance de fibroblastes |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201500125QA true SG11201500125QA (en) | 2015-02-27 |
Family
ID=48874535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201500125QA SG11201500125QA (en) | 2012-07-11 | 2013-07-11 | Inhibitors of the fibroblast growth factor receptor |
Country Status (26)
Country | Link |
---|---|
US (6) | US8802697B2 (fr) |
EP (1) | EP2872491B1 (fr) |
JP (1) | JP6104377B2 (fr) |
KR (2) | KR20200117067A (fr) |
CN (2) | CN104540809B (fr) |
AU (2) | AU2013290074A1 (fr) |
BR (1) | BR112015000653A2 (fr) |
CA (1) | CA2878412A1 (fr) |
CY (1) | CY1124414T1 (fr) |
DK (1) | DK2872491T3 (fr) |
ES (1) | ES2916220T3 (fr) |
HK (1) | HK1206023A1 (fr) |
HR (1) | HRP20211218T1 (fr) |
HU (1) | HUE055502T2 (fr) |
IL (1) | IL236611A (fr) |
LT (1) | LT2872491T (fr) |
MX (1) | MX369472B (fr) |
NZ (1) | NZ703495A (fr) |
PL (1) | PL2872491T3 (fr) |
PT (1) | PT2872491T (fr) |
RS (1) | RS62233B1 (fr) |
RU (2) | RU2019102203A (fr) |
SG (1) | SG11201500125QA (fr) |
SI (1) | SI2872491T1 (fr) |
WO (1) | WO2014011900A2 (fr) |
ZA (1) | ZA201500215B (fr) |
Families Citing this family (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
WO2012088266A2 (fr) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3 |
MY163674A (en) | 2011-07-01 | 2017-10-13 | Ngm Biopharmaceuticals Inc | Compositions, uses and method for treatment of metabolic disorders and diseases |
EP3822273B1 (fr) | 2012-06-13 | 2024-04-10 | Incyte Holdings Corporation | Composés tricycliques substitués servant d'inhibiteurs des fgfr |
PL2872491T3 (pl) | 2012-07-11 | 2021-12-13 | Blueprint Medicines Corporation | Inhibitory receptora czynnika wzrostu fibroblastów |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
EP3798228A1 (fr) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions et procédés pour le traitement de troubles métaboliques et de maladies |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
NZ630469A (en) | 2012-12-27 | 2017-02-24 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
AR095464A1 (es) | 2013-03-15 | 2015-10-21 | Celgene Avilomics Res Inc | Compuestos de heteroarilo y usos de los mismos |
UA120248C2 (uk) * | 2013-03-15 | 2019-11-11 | Селджен Кар Ллс | Гетероарильні сполуки та їх застосування |
US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
AU2014228746B2 (en) | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
TWI649318B (zh) | 2013-04-19 | 2019-02-01 | 英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
WO2015006492A1 (fr) | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase pour le traitement d'une maladie |
EP3035936B1 (fr) | 2013-08-23 | 2019-03-13 | NeuPharma, Inc. | Entités chimiques, compositions et méthodes particulières |
JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
PL3057969T3 (pl) | 2013-10-17 | 2018-11-30 | Blueprint Medicines Corporation | Kompozycje użyteczne do leczenia zaburzeń związanych z KIT |
RU2715708C2 (ru) | 2013-10-18 | 2020-03-03 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Ингибиторы fgfr4 |
TR201810944T4 (tr) | 2013-10-25 | 2018-08-27 | Novartis Ag | Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri. |
DK3395814T3 (da) | 2013-10-25 | 2022-07-04 | Blueprint Medicines Corp | Hæmmere af fibroblastvækstfaktorreceptoren |
US10369199B2 (en) | 2013-10-28 | 2019-08-06 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of cancer |
WO2015108992A1 (fr) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Composés hétérobicycliques et leur utilisation en tant qu'inhibiteurs du récepteur fgfr4 |
KR101922317B1 (ko) | 2014-01-20 | 2018-11-26 | 클리브 바이오사이언스 인코포레이티드 (클리브) | p97 복합체의 저해제로서 융합된 피리미딘 |
PT3097122T (pt) | 2014-01-24 | 2020-07-21 | Ngm Biopharmaceuticals Inc | Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos |
AU2015214328B2 (en) * | 2014-02-07 | 2019-04-18 | Principia Biopharma, Inc. | Quinolone derivatives as Fibroblast Growth Factor Receptor Inhibitors |
WO2015134210A1 (fr) | 2014-03-03 | 2015-09-11 | Principia Biopharma, Inc. | Dérivés de benzimidazole en tant qu'inhibiteurs de rlk et itk |
WO2015183890A2 (fr) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Méthodes et compositions pour le traitement de maladies et de troubles métaboliques |
AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
CN105017227B (zh) * | 2014-07-08 | 2018-03-09 | 四川百利药业有限责任公司 | N‑(1h‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物 |
BR112017002268B1 (pt) | 2014-08-18 | 2022-11-08 | Eisai R&D Management Co., Ltd | Sal de derivado de piridina monocíclica e cristal do mesmo |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
JP6585167B2 (ja) | 2014-10-03 | 2019-10-02 | ノバルティス アーゲー | Fgfr4阻害剤としての縮環二環式ピリジル誘導体の使用 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
RU2729161C2 (ru) | 2014-10-23 | 2020-08-04 | ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. | Фармацевтические композиции, содержащие варианты пептидов, и способы их применения |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
WO2016115412A1 (fr) * | 2015-01-18 | 2016-07-21 | Newave Pharmaceutical Llc | Inhibiteurs covalents de fgfr -4 à doubles "warheads" |
US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
US10947201B2 (en) * | 2015-02-17 | 2021-03-16 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
PE20171514A1 (es) | 2015-02-20 | 2017-10-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
MA41551A (fr) * | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
CN107667092B (zh) | 2015-03-25 | 2021-05-28 | 诺华股份有限公司 | 作为fgfr4抑制剂的甲酰化n-杂环衍生物 |
MX2017012979A (es) | 2015-04-10 | 2017-11-28 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y metodos de uso de los mismos. |
US10562888B2 (en) | 2015-04-14 | 2020-02-18 | Eisai R&D Management Co., Ltd. | Crystalline FGFR4 inhibitor compound and uses thereof |
JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Krasの縮合三環系インヒビターおよびその使用の方法 |
EP3298011B1 (fr) * | 2015-05-22 | 2021-11-17 | Principia Biopharma Inc. | Dérivés de quinolone utilisés en tant qu'inhibiteurs du récepteur du facteur de croissance des fibroblastes |
HUE055419T2 (hu) | 2015-06-03 | 2021-11-29 | Principia Biopharma Inc | Tirozinkináz-inhibitorok |
BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
BR112018001190A2 (pt) | 2015-07-24 | 2018-09-11 | Blueprint Medicines Corp | composições úteis para tratar distúrbios relacionados a kit e pdfgr |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
US10538518B2 (en) * | 2015-08-11 | 2020-01-21 | Principia Biopharma, Inc. | Processes for preparing an FGFR inhibitor |
AU2016311426B2 (en) | 2015-08-26 | 2021-05-20 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356339A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines mutantes kras g12c |
EP3356354A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines kras portant la mutation g12c |
EP3356351A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines kras portant la mutation g12c |
EP3356349A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines mutantes kras g12c |
MX2018004892A (es) | 2015-10-23 | 2018-12-10 | Array Biopharma Inc | Compuestos de 2-piridazin-3(2h)-ona 2-aril sustituidas y 2-heteroaril sustituidas como inhibidores de las tirosina quinasas fgfr. |
TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
HUE064659T2 (hu) | 2015-11-02 | 2024-04-28 | Blueprint Medicines Corp | RET inhibitorai |
AU2016353988B2 (en) | 2015-11-09 | 2019-09-26 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
RU2018122089A (ru) | 2015-11-19 | 2019-12-25 | Блюпринт Медсинс Корпорейшн | Соединения и композиции, подходящие для лечения расстройств, связанных с ntrk |
CN105669566A (zh) * | 2016-03-09 | 2016-06-15 | 华东师范大学 | 一种医药中间体n-芳基喹唑啉-2-胺化合物的制备方法 |
TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ret之抑制劑 |
TN2019000332A1 (en) | 2016-04-04 | 2021-05-07 | Loxo Oncology Inc | Methods of treating pediatric cancers |
WO2017176751A1 (fr) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
JP7372740B2 (ja) | 2016-05-10 | 2023-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ |
HUE063877T2 (hu) | 2016-05-18 | 2024-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása |
WO2018004258A1 (fr) * | 2016-06-28 | 2018-01-04 | 한미약품 주식회사 | Nouveau dérivé hétérocyclique et son utilisation |
KR20180002053A (ko) | 2016-06-28 | 2018-01-05 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
WO2018017983A1 (fr) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Composés utiles pour traiter des troubles liés à ret |
US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
AU2017312561B2 (en) | 2016-08-15 | 2022-06-30 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
KR102270620B1 (ko) | 2016-09-01 | 2021-06-30 | 난징 트렌스테라 바이오사이언스즈 컴퍼니 리미티드 | 섬유아세포 성장 인자 수용체의 억제제 및 이의 용도 |
US20190192522A1 (en) | 2016-09-08 | 2019-06-27 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors |
WO2018055503A1 (fr) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combinaison comprenant un antagoniste de pd-1 et un inhibiteur de fgfr4 |
US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
JP2019534260A (ja) | 2016-10-07 | 2019-11-28 | アラクセス ファーマ エルエルシー | Rasの阻害剤としての複素環式化合物およびその使用方法 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
WO2018072707A1 (fr) * | 2016-10-18 | 2018-04-26 | 保诺科技(北京)有限公司 | Dérivé d'éther aromatique, son procédé de préparation, et ses applications médicales |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
AU2017354082B2 (en) | 2016-11-02 | 2023-07-27 | Novartis Ag | Combinations of FGFR4 inhibitors and bile acid sequestrants |
WO2018090973A1 (fr) * | 2016-11-17 | 2018-05-24 | 广东众生药业股份有限公司 | Inhibiteur de fgfr4, son procédé de préparation et son utilisation |
KR101812266B1 (ko) | 2016-11-25 | 2017-12-27 | 한국과학기술연구원 | 4-((2-아크릴아미도페닐)아미노)티에노[3,2-d]피리미딘-7-카복스아미드 유도체 및 그의 약학적 활용 |
RU2747260C2 (ru) | 2016-12-19 | 2021-04-29 | Аббиско Тхерапеутицс Цо., Лтд. | Ингибитор рфрф4, способ его получения и его фармацевтическое применение |
CN108239069B (zh) * | 2016-12-26 | 2021-01-05 | 南京药捷安康生物科技有限公司 | 一种用于成纤维细胞生长因子受体的抑制剂及其用途 |
CN108264511B (zh) * | 2017-01-03 | 2021-04-13 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和其在医药上的用途 |
WO2018136663A1 (fr) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Inhibiteurs de ret |
CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
WO2018140513A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer |
EP3573970A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer |
WO2018140600A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Composés hétéro-hétéro-bicycliques fusionnés et leurs procédés d'utilisation |
US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
CN108503593B (zh) * | 2017-02-28 | 2021-04-27 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
WO2018218071A1 (fr) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Composés et leurs procédés d'utilisation pour le traitement du cancer |
JP2020521742A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | Krasの共有結合性阻害剤 |
EP3630747A1 (fr) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EP3444275A1 (fr) | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Anticorps monoclonaux anti-fgfr4 |
CA3074885A1 (fr) | 2017-09-05 | 2019-03-14 | Bioardis Llc | Derive aromatique, son procede de preparation, et ses applications medicales |
TW202410896A (zh) | 2017-10-10 | 2024-03-16 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
ES2931537T3 (es) | 2017-10-18 | 2022-12-30 | Blueprint Medicines Corp | Pirrolopiridinas sustituidas como inhibidores de la quinasa similar al receptor de activina |
KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
WO2019085894A1 (fr) * | 2017-10-30 | 2019-05-09 | 如东凌达生物医药科技有限公司 | Composé cyclique fusionné contenant de l'azote, son procédé de préparation et son utilisation |
US11603374B2 (en) | 2018-01-18 | 2023-03-14 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
WO2019154364A1 (fr) * | 2018-02-08 | 2019-08-15 | 南京明德新药研发有限公司 | Composé de pyrazine-2(1h)-cétone agissant en tant qu'inhibiteur de fgfr |
KR20200135945A (ko) | 2018-03-28 | 2020-12-04 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 간세포 암종 치료제 |
BR112020020273A2 (pt) | 2018-04-03 | 2021-04-06 | Blueprint Medicines Corporation | Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret |
CN110386921A (zh) * | 2018-04-23 | 2019-10-29 | 南京药捷安康生物科技有限公司 | 成纤维细胞生长因子受体抑制剂化合物 |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
AU2019262195A1 (en) | 2018-05-04 | 2020-12-24 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
WO2019223766A1 (fr) * | 2018-05-25 | 2019-11-28 | 上海和誉生物医药科技有限公司 | Inhibiteur de fgfr, son procédé de préparation et son utilisation pharmaceutique |
CN110577524B (zh) * | 2018-06-07 | 2022-01-28 | 北京大学深圳研究生院 | 一种激酶选择性抑制剂 |
WO2019242689A1 (fr) * | 2018-06-22 | 2019-12-26 | 北京赛特明强医药科技有限公司 | Composé de pyridine à substitution cyano et composé de pyrimidine à substitution cyano, procédé de préparation correspondant et utilisation associée |
CN113194928A (zh) | 2018-07-31 | 2021-07-30 | 罗索肿瘤学公司 | (s)-5-氨基-3-(4-((5-氟-2-甲氧基苯甲酰胺基)甲基)苯基)-1-(1,1,1-三氟丙-2-基)-1h-吡唑-4-甲酰胺的喷雾干燥的分散体和制剂 |
US11964988B2 (en) | 2018-09-10 | 2024-04-23 | Array Biopharma Inc. | Fused heterocyclic compounds as RET kinase inhibitors |
AU2019338992B2 (en) * | 2018-09-14 | 2022-01-20 | Abbisko Therapeutics Co., Ltd. | FGFR inhibitor, preparation method therefor and application thereof |
CN110950867A (zh) * | 2018-09-27 | 2020-04-03 | 首药控股(北京)有限公司 | 一种fgfr4激酶抑制剂及其制备方法和用途 |
CN111138459B (zh) * | 2018-11-06 | 2022-10-18 | 南京圣和药业股份有限公司 | Fgfr4抑制剂的光学异构体及其应用 |
WO2020119606A1 (fr) * | 2018-12-10 | 2020-06-18 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Composés hétérocycliques utilisés en tant qu'inhibiteurs du récepteur du facteur de croissance des fibroblastes |
US20220041579A1 (en) | 2018-12-19 | 2022-02-10 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases |
WO2020131627A1 (fr) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Composés pyrazolo[1,5-a]pyridine substitués servant d'inhibiteurs de tyrosine kinases fgfr |
WO2020177067A1 (fr) * | 2019-03-05 | 2020-09-10 | Bioardis Llc | Dérivés aromatiques, procédés de préparation et utilisations médicales de ceux-ci |
JP7378488B2 (ja) * | 2019-03-08 | 2023-11-13 | ショウヤオ ホールディングス(ベイジン) カンパニー, リミテッド | Fgfr4キナーゼ阻害剤、その製造方法及び用途 |
WO2020185532A1 (fr) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr |
MA53759A (fr) | 2019-04-12 | 2021-08-04 | Blueprint Medicines Corp | Formes cristallines de (s)-1-(4-fluorophényl)-1-(2-(4-(6-(1-méthyl-1h-pyrazol-4-yl))pyrrolo[2,1-f][1,2,4]triazin-4-yl)pipérazinyl)-pyrimidin-5-yl)éthan-1-amine et des procédés de fabrication |
CN110317176A (zh) * | 2019-07-04 | 2019-10-11 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
AU2020320997B2 (en) * | 2019-07-26 | 2023-07-27 | Cgenetech (Suzhou, China) Co., Ltd. | Pyridine derivative as FGFR and VEGFR dual inhibitors |
ES2954774T3 (es) * | 2019-08-08 | 2023-11-24 | Zhangzhou Pien Tze Huang Pharm | Forma cristalina A y forma cristalina B del compuesto de pirazina-2(1H)-cetona y su método de preparación |
US11535609B2 (en) | 2019-08-08 | 2022-12-27 | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. | Pyrazine-2(1H)-ketone compound preparation method |
ES2968388T3 (es) * | 2019-08-08 | 2024-05-09 | Zhangzhou Pien Tze Huang Pharm | Forma cristalina D del compuesto pirazina-2(1H)-cetona y método para su preparación |
MX2022004513A (es) | 2019-10-14 | 2022-07-19 | Incyte Corp | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CN112759593A (zh) | 2019-11-01 | 2021-05-07 | 北京伯汇生物技术有限公司 | 桥环并醛基吡啶衍生物及其应用 |
PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
EP4069696A1 (fr) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
US20230125046A1 (en) | 2019-12-23 | 2023-04-20 | Beijing Scitech-Mq Pharmaceuticals Limited | Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof |
AU2020413333A1 (en) | 2019-12-27 | 2022-06-16 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
WO2021146424A1 (fr) * | 2020-01-15 | 2021-07-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
EP4161657A1 (fr) * | 2020-06-05 | 2023-04-12 | Kinnate Biopharma Inc. | Inhibiteurs des kinases du récepteur du facteur de croissance des fibroblastes |
CN116490507A (zh) | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
CN112851587A (zh) * | 2021-01-21 | 2021-05-28 | 药雅科技(上海)有限公司 | 一种用于治疗癌症的炔类杂环化合物及其制备方法与用途 |
US20240148732A1 (en) | 2021-01-26 | 2024-05-09 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
CN114853740B (zh) * | 2021-02-03 | 2023-08-01 | 药雅科技(上海)有限公司 | 炔类嘧啶化合物作为fgfr抑制剂的制备方法和用途 |
TWI820622B (zh) | 2021-03-04 | 2023-11-01 | 美商美國禮來大藥廠 | Fgfr3抑制劑化合物 |
WO2022194160A1 (fr) * | 2021-03-16 | 2022-09-22 | 上海启晟合研医药科技有限公司 | Forme solide de fisogatinib et son procédé de préparation |
TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
AU2021436754A1 (en) * | 2021-03-26 | 2023-10-12 | Apeloa Pharmaceutical Co., Ltd. | Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation comprising same, and application thereof |
WO2022261160A1 (fr) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
CN113912602B (zh) * | 2021-10-14 | 2023-05-05 | 温州医科大学 | 一种2-氧代-1,2-二氢-1,6-萘啶-7-基类化合物及其制备方法和用途 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US173074A (en) * | 1876-02-01 | Improvement in flour and meal bolts | ||
ES2146782T3 (es) * | 1994-11-14 | 2000-08-16 | Warner Lambert Co | 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa. |
IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
GB9708917D0 (en) * | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
PL344248A1 (en) * | 1998-05-26 | 2001-10-22 | Warner Lambert Co | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
TR200201057T2 (tr) * | 1999-10-21 | 2002-09-23 | F.Hoffmann-La Roche Ag | P38 protein kinazı inhibitörleri olarak heteroalkilamino ikameli bisiklik nitrojen heterosaykılları. |
US6403799B1 (en) | 1999-10-21 | 2002-06-11 | Agouron Pharmaceuticals, Inc. | Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors |
AU1462101A (en) | 1999-11-22 | 2001-06-04 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
AU2001245401A1 (en) | 2000-03-01 | 2001-09-12 | Sumitomo Pharmaceuticals Company, Limited | Hydrazones and analogs as cholesterol lowering agents |
MXPA02011263A (es) * | 2000-08-04 | 2003-03-10 | Warner Lambert Co | 2-(4-piridil)amino-6-dialcoxifenil- pirido(2,3-d) pirimidin-7-onas. |
WO2002076985A1 (fr) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Composes utiles en tant qu'inhibiteurs de kinases pour le traitement des maladies hyperproliferatives |
DK1470124T3 (da) | 2002-01-22 | 2006-04-18 | Warner Lambert Co | 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner |
US20050009849A1 (en) * | 2003-01-03 | 2005-01-13 | Veach Darren R. | Pyridopyrimidine kinase inhibitors |
WO2005030131A2 (fr) | 2003-09-23 | 2005-04-07 | Replidyne, Inc | Composes de bis-quinazoline pour le traitement des infections bacteriennes |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
EP1878727A4 (fr) * | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | Dérivés de 2-aminoquinazoline |
RU2009106722A (ru) * | 2006-07-28 | 2010-09-10 | Новартис АГ (CH) | 2,4-замещенные хиназолины в качестве ингибиторов липидной киназы |
AU2007337886C1 (en) | 2006-12-22 | 2014-10-16 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
KR20090092287A (ko) * | 2006-12-22 | 2009-08-31 | 노파르티스 아게 | Pdk1 억제를 위한 퀴나졸린 |
GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
MX357627B (es) * | 2008-06-27 | 2018-07-17 | Avila Therapeutics Inc | Compuestos de heteroarilo y usos de los mismos. |
CN102224170A (zh) | 2008-09-03 | 2011-10-19 | 利琴蒂亚有限公司 | 抑制与fgfr4相关的癌细胞侵袭的材料和方法 |
US20100185419A1 (en) * | 2008-09-05 | 2010-07-22 | Avila Therapeutics, Inc. | Algorithm for designing irreversible inhibitors |
CA2748319A1 (fr) | 2008-12-29 | 2010-07-08 | Fovea Pharmaceuticals | Composes quinazoline substitues de formule generale (i) et leurs utilisations pour le traitement de troubles relatifs au dereglement entraine par une tyrosine kinase |
TWI464160B (zh) | 2009-08-07 | 2014-12-11 | Chugai Pharmaceutical Co Ltd | Amino pyrazole derivative |
BR112012005962A8 (pt) * | 2009-09-16 | 2018-01-02 | Avila Therapeutics Inc | Conjugados de proteína quinase, compostos e composição farmacêutica compreendendo os referidos compostos |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
LT3505528T (lt) | 2011-04-21 | 2021-04-26 | Glaxo Group Limited | Hepatito b viruso (hbv) raiškos moduliacija |
DK2710007T3 (da) * | 2011-05-17 | 2020-01-27 | Principia Biopharma Inc | Kinasehæmmere |
FR2985257B1 (fr) * | 2011-12-28 | 2014-02-14 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
MX351513B (es) | 2012-01-19 | 2017-10-17 | Taiho Pharmaceutical Co Ltd | Compuesto de alquinilbenceno 3,5-disustituido y sales del mismo. |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
PL2872491T3 (pl) * | 2012-07-11 | 2021-12-13 | Blueprint Medicines Corporation | Inhibitory receptora czynnika wzrostu fibroblastów |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
WO2014044846A1 (fr) | 2012-09-24 | 2014-03-27 | Evotec (Uk) Ltd. | Dérivés de 3-(aryl- ou hétéroaryl-amino)-7-(3,5-diméthoxyphényl)isoquinoline comme inhibiteurs de fgfr utiles pour le traitement de troubles prolifératifs ou de la dysplasie |
TWI629266B (zh) * | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
MX363715B (es) | 2013-02-21 | 2019-03-29 | Pfizer | Formas solidas de un inhbidor de cdk4/6 selectivo. |
AU2014228746B2 (en) | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
AR095464A1 (es) * | 2013-03-15 | 2015-10-21 | Celgene Avilomics Res Inc | Compuestos de heteroarilo y usos de los mismos |
US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
EP3024155B1 (fr) | 2013-07-14 | 2018-10-03 | LG Electronics Inc. | Procédé d'émission de symboles de données à l'aide d'une corrélation d'antenne dans un système d'accès sans fil qui prend en charge une antenne massive |
WO2015058129A1 (fr) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Composés à utiliser pour traiter des troubles associés à l'enzyme kit |
PL3057969T3 (pl) | 2013-10-17 | 2018-11-30 | Blueprint Medicines Corporation | Kompozycje użyteczne do leczenia zaburzeń związanych z KIT |
RU2715708C2 (ru) | 2013-10-18 | 2020-03-03 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Ингибиторы fgfr4 |
DK3395814T3 (da) | 2013-10-25 | 2022-07-04 | Blueprint Medicines Corp | Hæmmere af fibroblastvækstfaktorreceptoren |
TR201810944T4 (tr) | 2013-10-25 | 2018-08-27 | Novartis Ag | Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri. |
WO2015108992A1 (fr) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Composés hétérobicycliques et leur utilisation en tant qu'inhibiteurs du récepteur fgfr4 |
US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
US20160115164A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
PE20171514A1 (es) | 2015-02-20 | 2017-10-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
BR112018001190A2 (pt) | 2015-07-24 | 2018-09-11 | Blueprint Medicines Corp | composições úteis para tratar distúrbios relacionados a kit e pdfgr |
AU2016311426B2 (en) | 2015-08-26 | 2021-05-20 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
MX2018004892A (es) | 2015-10-23 | 2018-12-10 | Array Biopharma Inc | Compuestos de 2-piridazin-3(2h)-ona 2-aril sustituidas y 2-heteroaril sustituidas como inhibidores de las tirosina quinasas fgfr. |
HUE064659T2 (hu) | 2015-11-02 | 2024-04-28 | Blueprint Medicines Corp | RET inhibitorai |
RU2018122089A (ru) | 2015-11-19 | 2019-12-25 | Блюпринт Медсинс Корпорейшн | Соединения и композиции, подходящие для лечения расстройств, связанных с ntrk |
TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ret之抑制劑 |
FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
WO2018017983A1 (fr) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Composés utiles pour traiter des troubles liés à ret |
US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
US20190192522A1 (en) | 2016-09-08 | 2019-06-27 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors |
-
2013
- 2013-07-11 PL PL13740458T patent/PL2872491T3/pl unknown
- 2013-07-11 CN CN201380042618.8A patent/CN104540809B/zh active Active
- 2013-07-11 MX MX2015000405A patent/MX369472B/es active IP Right Grant
- 2013-07-11 KR KR1020207028352A patent/KR20200117067A/ko active IP Right Grant
- 2013-07-11 DK DK13740458.8T patent/DK2872491T3/da active
- 2013-07-11 AU AU2013290074A patent/AU2013290074A1/en not_active Abandoned
- 2013-07-11 EP EP13740458.8A patent/EP2872491B1/fr active Active
- 2013-07-11 RU RU2019102203A patent/RU2019102203A/ru unknown
- 2013-07-11 RU RU2015104342A patent/RU2679130C2/ru active
- 2013-07-11 CA CA2878412A patent/CA2878412A1/fr not_active Abandoned
- 2013-07-11 PT PT137404588T patent/PT2872491T/pt unknown
- 2013-07-11 SI SI201331919T patent/SI2872491T1/sl unknown
- 2013-07-11 SG SG11201500125QA patent/SG11201500125QA/en unknown
- 2013-07-11 NZ NZ703495A patent/NZ703495A/en not_active IP Right Cessation
- 2013-07-11 ES ES13740458T patent/ES2916220T3/es active Active
- 2013-07-11 BR BR112015000653A patent/BR112015000653A2/pt active Search and Examination
- 2013-07-11 CN CN201811201617.4A patent/CN109627239B/zh active Active
- 2013-07-11 US US13/939,967 patent/US8802697B2/en active Active
- 2013-07-11 HU HUE13740458A patent/HUE055502T2/hu unknown
- 2013-07-11 JP JP2015521815A patent/JP6104377B2/ja active Active
- 2013-07-11 WO PCT/US2013/050106 patent/WO2014011900A2/fr active Application Filing
- 2013-07-11 KR KR1020157003581A patent/KR102163776B1/ko active IP Right Grant
- 2013-07-11 RS RS20210986A patent/RS62233B1/sr unknown
- 2013-07-11 LT LTEP13740458.8T patent/LT2872491T/lt unknown
-
2014
- 2014-06-27 US US14/318,149 patent/US9126951B2/en active Active
-
2015
- 2015-01-11 IL IL236611A patent/IL236611A/en active IP Right Grant
- 2015-01-13 ZA ZA2015/00215A patent/ZA201500215B/en unknown
- 2015-04-02 US US14/677,162 patent/US9340514B2/en active Active
- 2015-07-13 HK HK15106652.9A patent/HK1206023A1/xx unknown
-
2016
- 2016-04-13 US US15/097,995 patent/US20170066812A1/en not_active Abandoned
-
2017
- 2017-12-07 AU AU2017272281A patent/AU2017272281B2/en not_active Ceased
-
2018
- 2018-01-10 US US15/867,637 patent/US10196436B2/en active Active
- 2018-12-21 US US16/231,184 patent/US20190359682A1/en not_active Abandoned
-
2021
- 2021-07-28 HR HRP20211218TT patent/HRP20211218T1/hr unknown
- 2021-08-03 CY CY20211100691T patent/CY1124414T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1206023A1 (en) | Inhibitors of the fibroblast growth factor receptor | |
HK1221460A1 (zh) | 纖維母細胞生長因子受體抑制劑 | |
HK1210775A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
HK1200828A1 (en) | Kinase inhibitors | |
HK1205431A1 (en) | Solid forms of an epidermal growth factor receptor kinase inhibitor | |
EP2710007A4 (fr) | Inhibiteurs de kinase | |
GB201211310D0 (en) | CSF-1R kinase inhibitors | |
IL229028A0 (en) | Kinase inhibitors | |
HK1199873A1 (en) | Kinase inhibitors | |
HK1213252A1 (zh) | 雙環二氫吡啶酮激酶抑制劑 | |
SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
HK1209105A1 (en) | Vegfr3 inhibitors vegfr3 | |
HK1209104A1 (en) | Vegfr3 inhibitors vegfr3 | |
HK1213181A1 (zh) | 雙環氧雜內酰胺激酶抑制劑 |